Full-Time

Specialist Medical Information

Global Consulting Services

Posted on 9/9/2025

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Jackson Township, NJ, USA

Remote

Candidates must be based in the United States.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Marketing
Requirements
  • Professional education or University degree in Life Science
  • 2-3 years Medical Information experience
  • Basic understanding/knowledge in the field of pharmacovigilance is desirable
  • Comfortable monitoring phone calls as a significant part of this role
  • Ability to prioritize and manage own time and tasks
  • Ability to manage internal and external (client) relationships on operational / day-to-day working level as well as client's team lead level
  • Good communication skills (written and verbally); capability to point out issues and provide potential options for solution in the area of expertise
  • English business fluent
Responsibilities
  • Support remotely-managed call center by managing inbound calls and emails, providing accurate, timely, and compliant responses to healthcare professionals, patients, and other stakeholders.
  • Address Medical Information requests (MIR) from multiple programs and sources using approved response documents.
  • Ensure that all the MIR are processed and documented according to GCS and client procedures, and project working practice.
  • Identify and document adverse events (AE), product complaints, and quality issues according to GCS and clients procedures.
  • Report AE information to the pharmacovigilance department.
  • Collaborate with GCS and client's internal teams, including regulatory, medical affairs and marketing to provide scientific support as needed.
  • Participate in client's product training, diseases and therapeutic areas, as per project requirement.
  • Support project team on any report clarification, metrics, volumes, KPIs and compliance investigations.
  • Escalate L2 MIR as per project agreement.
  • Support in internal and external audits.
  • Perform quality control of MIR to ensure adherence to project requirements and procedures.
  • Reconcile medical information reports with adverse events and product quality complaint reports within the agreed timelines.
  • The employee agrees to take over primary listed tasks and responsibilities in other service lines, project management activities as client contact point and additional reasonable tasks that align with their abilities, qualification and training, if required.
Desired Qualifications
  • Basic understanding/knowledge in the field of pharmacovigilance is desirable

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Simplify Jobs

Simplify's Take

What believers are saying

  • Specialty pharmaceuticals remain the main growth engine for higher-margin services.
  • Management targets $300 million in savings while sustaining about $3 billion free cash flow.
  • Share repurchases and accretive acquisitions can support earnings per share.

What critics are saying

  • Biosimilar conversions are cutting revenue growth at major mail-order pharmacy customers.
  • Manufacturer list-price cuts created a $2 billion quarterly revenue headwind.
  • Customer losses and slower GLP-1 growth weaken Cencora's specialty mix.

What makes Cencora unique

  • Cencora combines drug distribution, specialty pharmacy, and patient-support services.
  • It operates globally, serving manufacturers, providers, pharmacies, and veterinary customers.
  • The company is expanding specialty care through OneOncology and EyeSouth retina assets.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Cencora who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.

INACTIVE